HeartBeam has been ranked second worldwide in 12-lead ECG innovation among 243 firms analyzed, according to PatentVest's "Total Cardiac Intelligence" report, trailing only GE Healthcare in this global assessment of portable cardiac diagnostics innovation. This recognition highlights the company's growing influence in the next generation of cardiac monitoring technology and underscores the rapid maturation of its proprietary synthesis-ECG system. The system captures the heart's electrical signals in three noncoplanar dimensions and synthesizes them into a 12-lead ECG, allowing physicians to obtain cardiologist-level ECG data from compact devices that can be used by patients or clinicians far from traditional hospital settings.
This unique approach addresses one of modern medicine's most persistent challenges: delivering high-quality cardiac monitoring for arrhythmia assessment wherever patients are. The company is cleared for arrhythmia today, with ischemia monitoring as a future goal. HeartBeam is creating the first-ever cable-free 12-lead ECG capable of capturing the heart's electrical signals from three dimensions, with this platform technology designed to be used in portable devices that can deliver actionable heart intelligence wherever the patient is. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to appropriate care outside of medical facilities, potentially redefining the future of cardiac health management.
The company holds 13 U.S. and 4 international-issued patents related to technology enablement, with more information available at https://www.HeartBeam.com. Additional news and updates are available through the company's newsroom at https://ibn.fm/BEAT. The implications of this recognition extend beyond corporate achievement to potential healthcare transformation, as cardiac monitoring technology becomes more portable and accessible.
Patients in remote or underserved areas could receive the same quality of cardiac assessment as those in major medical centers, potentially leading to earlier detection of cardiac issues, more timely interventions, and reduced healthcare costs by minimizing unnecessary hospital visits while ensuring appropriate care reaches those who need it most. This advancement represents a significant step toward democratizing cardiac diagnostics and making sophisticated medical technology available beyond traditional clinical settings, potentially improving outcomes for millions of patients worldwide who lack immediate access to specialized cardiac care facilities.
